Navigation Links
Alfacell Reports Financial Results for First Quarter of Fiscal 2008
Date:12/10/2007

olled in the trial. The company plans to begin the required statistical analysis of the data generated by the trial after 316 evaluable events have occurred. A total of 307 evaluable events have occurred to date.

The U.S. Food and Drug Administration (FDA) granted ONCONASE fast track status and orphan-drug designation for treatment of malignant mesothelioma. The rolling NDA submission for ONCONASE is in process, and Alfacell plans to submit the final clinical section within four months of reporting 316 evaluable events.

The company is focused on the imminent completion of the confirmatory Phase IIIb clinical trial and completion of the rolling NDA, and intends to initiate its planned Phase II oncology program for ONCONASE after the end of the Phase IIIb clinical trial.

Conference Call & Webcast

Alfacell will host a conference call and Webcast to discuss the financial results at 11 a.m. EST on Monday, Dec. 10. To participate in the live conference call, U.S. residents may dial 1-877-407-9205, and international callers may dial 1-201-689-8054 and reference Alfacell. A replay of the call will be available until Dec. 17. To access the replay, U.S. residents may dial 1-877-660-6853, and international callers may dial 1-201-612-7415 and enter account number 286 and conference ID number 264176. A live Webcast and replay of the conference call will be available on Alfacell's Web site at http://www.alfacell.com.

About ONCONASE(R)

ONCONASE is a first-in-class therapeutic product candidate based on Alfacell's proprietary ribonuclease (RNase) technology. A natural protein isolated from the leopard frog, ONCONASE has been shown in the laboratory and clinic to target cancer cells while sparing normal cells. ONCONASE triggers apoptosis, the natural death of cells, via multiple molecular mechanisms of action.

About Alfacell Corporation

Alfacell Corporation is the first compan
'/>"/>

SOURCE Alfacell Corporation
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
2. Alfacell Updates Status of ONCONASE(R) Phase III Clinical Program
3. Alfacell Corporation to Present at UBS Global Life Sciences Conference
4. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
5. Spherix Reports Second Quarter Earnings
6. Tapestry Reports Second Quarter 2007 Results
7. Callisto Reports on Second-Quarter 2007 Milestones
8. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
9. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
10. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
11. Biopure Reports on Meeting with the FDA

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/20/2009)...Newswire-FirstCall/ -- Cyberonics, Inc. (Nasdaq: ...nd Chief Executive Officer, and Greg Browne, Chief...l Piper Jaffray Health Care Conference in New York...The conference session and webcast will be audio o... Jaffray will host a webcast of the presentation l...
(Date:11/20/2009)...ov. 20 BD (Becton, Dicki...he completion of its acquisition of HandyLab, Inc....ps and manufactures molecular diagnostic assays an...HandyLab announced an exclusive agreement for BD t...e HandyLab Jaguar(TM) platform, the first fully in...
(Date:11/20/2009)... 20 Soligenix, Inc. (OTC... formerly known as DOR BioPharma, Inc., a late-sta...has formed a consortium to develop thermostable te...ting vaccines. Soligenix received a $9.4 million g...fectious Diseases (NIAID), a division of the Natio...
Breaking Medicine Technology:Cyberonics to Present at 21st Annual Piper Jaffray Health Care Conference 2BD Completes Acquisition of HandyLab, Inc. 2BD Completes Acquisition of HandyLab, Inc. 3Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 2Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 3Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 4Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 5Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 6Unifi Med 5 0 Complete EMR and Practice Management Solution 5426 1Unifi Med 5 0 Complete EMR and Practice Management Solution 5426 2U S Patent Issued for Champions Biotechnologys Lead Oncology Drug 5424 1U S Patent Issued for Champions Biotechnologys Lead Oncology Drug 5424 2U S Patent Issued for Champions Biotechnologys Lead Oncology Drug 5424 3Kendle Announces Details Regarding Third Quarter 2009 Earnings Conference Call and Webcast 5422 1Kendle Announces Details Regarding Third Quarter 2009 Earnings Conference Call and Webcast 5422 2
...y to Submit a Supplemental New Drug Application to...April 6 Cephalon, Inc . (Nasdaq: CEPH ) today ...ical trial of NUVIGIL(R) (armodafinil) Tablets [C-...ated with jet lag disorder. Based on these findin...Application with the U.S. Food and Drug Administra...
...CORE Phase II Testing Certification with Edifecs C...es that are now required in X12 Version 5010 , , ...y that it will, together with its partners CAQH an...s and lessons learned from the CORE Phase II Certi...andated 5010 Rules, in a presentation at the HIMSS...
Other Medicine Technology:Cephalon Announces Positive Results from a Phase Three Study of NUVIGIL in Jet Lag Disorder 2Cephalon Announces Positive Results from a Phase Three Study of NUVIGIL in Jet Lag Disorder 3Cephalon Announces Positive Results from a Phase Three Study of NUVIGIL in Jet Lag Disorder 4Edifecs, CAQH and Harvard Pilgrim Health Care Will Examine CORE Phase II Testing Outcomes and Lessons Learned at HIMSS09 Interoperability Showcase 2Edifecs, CAQH and Harvard Pilgrim Health Care Will Examine CORE Phase II Testing Outcomes and Lessons Learned at HIMSS09 Interoperability Showcase 3Edifecs, CAQH and Harvard Pilgrim Health Care Will Examine CORE Phase II Testing Outcomes and Lessons Learned at HIMSS09 Interoperability Showcase 4Edifecs, CAQH and Harvard Pilgrim Health Care Will Examine CORE Phase II Testing Outcomes and Lessons Learned at HIMSS09 Interoperability Showcase 5
(Date:11/21/2009)... Eric J. Hall, president and chief e...America (AFA) issued the following statement regar...on as part of the new annual wellness for Medicare... Affordable Care Act" that was introduced las...PRWEB) November 21, 2009 -- Eric J. Hall, presiden...
(Date:11/20/2009)...Pioneering Neurologist Closer to Understanding Bra...PRNewswire-USNewswire/ -- Dr. Jeremy Schmahmann, P...d neurologist at the Massachusetts General Hospita...is laboratory,s research on the new field of study...nk Foundation. ,, Dr. Schmahmann is an award-wi...
(Date:11/20/2009)..., WASHINGTON, Nov. 20 /PRNewswire-USNewswire/ -... urged the Senate to make essential changes its he... law on abortion funding and conscience protection...migrants and include strong provisions for adequat...te health care bill an "enormous disappointment" t...
(Date:11/20/2009)..., MADISON, N.J., Nov. 20 /PRNewswire-FirstCall/ -...rus may have peaked in late October, but the pande...f illness in all age groups, including the elderly...ncorporated (NYSE: DGX ), the world,s leading pr...ices. ,, In its most recent Quest Diagnostics ...
(Date:11/20/2009)..., HAIFA, Israel, November 20 /PRNewswire-Firs...SL.OB), http://www.CVSLMEDICAL.COM , a leading,de...ogy, today announced that,the company,s Board of D...ns,in Europe, Canada and the Far East for its prop...icable for all angioplasty (PCTA) procedures. ,...
Breaking Medicine News(10 mins):Health News:Alzheimer's Foundation of America Applauds Inclusion of Cognitive Impairment Detection in Healthcare Reform 2Health News:Alzheimer's Foundation of America Applauds Inclusion of Cognitive Impairment Detection in Healthcare Reform 3Health News:MINDlink Foundation Launches to Connect the Cerebellum to Cures 2Health News:U.S. Bishops Voice Disappointment in Abortion-Funding Provisions in Senate Health Bill, Urge Better Care for Immigrants and Affordability 2Health News:H1N1 Pandemic May Have Peaked in October in U.S., According to Quest Diagnostics 2Health News:H1N1 Pandemic May Have Peaked in October in U.S., According to Quest Diagnostics 3Health News:Cardio Vascular Medical Device to Apply for Additional Patents in Europe, Canada and Far East 2
... Gujarat Government seeks to bring down infant and...lth program. As many as 5,000 // mothers and 72,0...ate. Through this new program named Chiranj... mortality rate to come down to 30 per thousand bi...
...porters of the Communist Party of India-Marxist (C...January 2006. The supporters of the guru are // ...MP Brinda Karat, who leveled charges that the medi...the office of the party. Health Minister ...
...what can be called as a rare feat, cardio-thoracic...ormed surgical correction of a congenital heart de... anesthesia’. // This surgery has so far been done...ng the entire surgery. The sensation of pain would...
...ect injection of chemotherapeutic agents into dire...onal intravenous route, seems to be // associated...ents, according to a latest study. // Ovari...f treatment for all ovarian cancer patients. ...
... incidence of waterborne diseases and food poisoni...ummer. An increase in the number of malaria cases ... cases is hoped to soar particularly, as people wo...bility of a well-developed public health system in...
...ted Kingdom Ministry is planning for reduction of ...re surgery. The Government is planning to reduce t... weeks from time of admission to NHS. Government i...tic and scan tests and also have to wait for speci...
Other Medicine News:Health News:Death Risk Of Ovarian Cancer Reduced By Intraperitoneal Chemotherapy 2Health News:Rise In Waterborne And Malaria Cases Anticipated In Britain 2
... American standard, corrected curve trial lenses a...ed in Marco refractors and are invaluable in treat...ets of other manufacturers contain a disproportion...which are less expensive to produce, and fewer len...
Marco LM-990A
LM-770 Digital Projection Lensemeter
EPIC
Medicine Products: